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Background/introduction
MRI-guided transurethral ultrasound ablation (TULSA)
is a new minimally-invasive modality for the treatment
of prostate cancer, which aims to provide local disease
control with low morbidity. A transurethral ultrasound
device generates a continuous volume of thermal coagu-
lation that is shaped precisely to the prostate using real-
time MR thermometry and active temperature feedback
control. The aim of this multi-center, prospective Phase
I clinical study is to determine the safety and feasibility
of MRI-guided TULSA, and to assess initial efficacy for
treatment of localized prostate cancer.
Methods
A total of 30 patients were enrolled with biopsy-proven,
low-risk, localized prostate cancer: age ≥ 65 years, clinical
stage T1c/T2a, PSA ≤ 10ng/ml, Gleason Score ≤ 3+3 (3+4
max in Canada only). Treatment was completed under
general anesthesia and drainage from a suprapubic catheter
(SPC) which remains for 2 weeks. Treatment planning was
performed under MRI prostate visualization, with thera-
peutic intent of whole–gland ablation. Treatment was
delivered under continuous MR thermometry active feed-
back control. Primary endpoints are safety and feasibility,
with follow-up to 12 months. Complete clinical monitoring
is 5 years, including serial PSA, completion of quality-of-
life-questionnaires and prostate biopsy at 12 months.
Results and conclusions
Median (range) prostate volume and treatment time were
47 (21-95) cc and 36 (24-61) min, respectively (n=30). MR
thermometry measurements depict a continuous region of
heating with a high degree of spatial control of the ablation
volume, to within 0.1 ± 1.3 mm (n=30). Median PSA
reduced by 90% (60 – 99%) to 0.7 ng/ml at 1 month
(n=28), remaining stable to 0.6 ng/ml at 6 months (n=20).
MRI-guided TULSA was well-tolerated by all patients, with
no intraoperative complications, and no reported cases of
urinary incontinence, fistula or rectal injury. All complica-
tions to-date were CTCAE v4 Grade 1-3 and included:
hematuria (15), urinary tract infection (10), epididymitis
(1), and acute urinary retention (4) requiring prolonged or
re-catheterization. Normal micturition returned after SPC
removal, with return to baseline by 3 months (n=26) and
improvement by 6 months (n=21): IPSS median score 9
(baseline) to 6 (6 months), and peak urinary flow 14 ml/s
(baseline) to 19 ml/s (6 months). MRI-guidance enables
accurate planning and real-time dosimetry and control of
the thermal ablation volume. Midterm results indicate that
MRI-guided TULSA is safe and clinically feasible with a
well-tolerated, low side effect profile.
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